Based on our prophase study results [13], we further demonstrated that Neoadj-Chemo affects not only the EGFR mutation status, but also the aberrant mutation status of EGFR related downstream or bypass genes in NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.